Novo Nordisk's CagriSema Falls Short of Tirzepatide in Head-to-Head Trial
Event summary
- Novo Nordisk's CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) achieved 23% weight loss after 84 weeks in the REDEFINE 4 trial.
- The trial, comparing CagriSema to tirzepatide 15 mg, failed to demonstrate non-inferiority in weight loss.
- Tirzepatide 15 mg achieved 25.5% weight loss in the same trial.
- Novo Nordisk submitted CagriSema to the US FDA in December 2025 and anticipates a decision by late 2026.
- A higher-dose CagriSema trial is planned for the second half of 2026.
The big picture
The REDEFINE 4 results highlight the intensifying competition in the rapidly growing obesity treatment market. While CagriSema's 23% weight loss is substantial, failing to demonstrate non-inferiority to tirzepatide raises questions about its value proposition and pricing power. Novo Nordisk's commitment to further trials and higher doses underscores the ongoing investment required to capture a significant share of this multi-billion dollar market.
What we're watching
- Regulatory Risk
- The FDA decision on CagriSema, now anticipated without the non-inferiority data, will be critical and could significantly impact its market launch and commercial prospects.
- Clinical Execution
- The success of the higher-dose CagriSema trial, slated to begin in 2H 2026, will be essential to demonstrate the drug's full potential and offset the current setback.
- Competitive Landscape
- Novo Nordisk will need to closely monitor tirzepatide's continued market penetration and any emerging GLP-1/amylin combination therapies to maintain a competitive edge in the obesity treatment space.
Related topics